JNJ-38877605

JNJ-38877605 is an orally bioavailable small molecule that acts as a highly selective ATP competitive inhibitor of c-Met (hepatocyte growth factor receptor), a receptor tyrosine kinase involved in cancer cell survival and invasiveness as well as tumor angiogenesis. By inhibiting c-Met signaling pathways—including RAS/ERK and PI3K/AKT—JNJ‑38877605 was developed for its potential antineoplastic activity. It demonstrated potent anti-tumor effects in preclinical models of prostate cancer, non-small cell lung cancer (NSCLC), gastric cancer and glioblastoma. The drug was initially developed by Johnson & Johnson for the treatment of neoplasms but clinical development was discontinued due to species-specific renal toxicity observed in humans during phase I trials.[1][2][3][4][5][6]

Other names

943540-75-86-(difluoro(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)quinoline6-[difluoro-[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl]quinoline